Saina Attaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Saina Attaran has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Brian M. Fabri
Liverpool Heart and Chest Hospital, Liverpool , UK
7 shared publications- Matthew Shaw
Institute of Cardiovascular Medicine and Science, Department of Cardiology, Liverpool Heart and Chest Hospital, Thomas Drive, Liverpool, L14 3PE, UK
7 shared publications Mark D. Pullan
6 shared publicationsMark Field
Thoracic Aortic Aneurysm Service, Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK
6 shared publicationsAung Oo
Thoracic Aortic Aneurysm Service, Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK
5 shared publicationsLaura Bond
5 shared publications
Latest Publications
- Open Access
- 21 November 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 16 (3) , 347-349
Is coronary artery bypass grafting an acceptable alternative to myotomy for the treatment of myocardial bridging?
A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was ‘Is CABG an effective alternative for the treatment of myocardial bridging?’ Altogether, only six papers were identified using the reported search that represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes, and results of these papers are tabulated; these studies reported the outcome of myotomy and coronary artery bypass grafting (CABG) for myocardial bridging. All of these studies were retrospective reports of the results of surgical intervention in patients with myocardial bridging. They showed that the incidence of myocardial bridging was less than 1–1.5% in patients with angina requiring angiography, and 7–9% of these patients had refractory angina despite medical treatment and required surgery. The evidence on the treatment of this congenital condition that mainly affects the middle segment of left anterior descending artery is limited, and there are no treatment guidelines currently available. Stenting of the tunnelled segment has shown high failure rates in approximately half of the cases. Current evidence in the literature suggests that surgery is the mainstay treatment for myocardial bridging. Surgery is performed either as supra-arterial myotomy and de-roofing of the muscle bands on- or off-pump, or as coronary artery bypass grafting of the affected coronary artery beyond the tunnelled segment. Although no mortality was reported with either of these operations, surgical myotomy on deep and extensive myocardial bridges carries the risk of entering the right ventricle, bleeding and aneurysm formation. In addition, in a small percentage of the patients undergoing myotomy, angina recurred. Despite the possibility of competitive flow in the native coronary artery after CABG for myocardial bridging, we did not identify any evidence demonstrating graft occlusion after CABG for myocardial bridging. In conclusion, in extensive and deep myocardial bridgings, CABG may be the treatment of choice that carries low risk, limited complications and excellent symptomatic relief.
- 21 November 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 16 (3) , 347-349
Open AccessIs coronary artery bypass grafting an acceptable alternative to myotomy for the treatment of myocardial bridging?
A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was ‘Is CABG an effective alternative for the treatment of myocardial bridging?’ Altogether, only six papers were identified using the reported search that represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes, and results of these papers are tabulated; these studies reported the outcome of myotomy and coronary artery bypass grafting (CABG) for myocardial bridging. All of these studies were retrospective reports of the results of surgical intervention in patients with myocardial bridging. They showed that the incidence of myocardial bridging was less than 1–1.5% in patients with angina requiring angiography, and 7–9% of these patients had refractory angina despite medical treatment and required surgery. The evidence on the treatment of this congenital condition that mainly affects the middle segment of left anterior descending artery is limited, and there are no treatment guidelines currently available. Stenting of the tunnelled segment has shown high failure rates in approximately half of the cases. Current evidence in the literature suggests that surgery is the mainstay treatment for myocardial bridging. Surgery is performed either as supra-arterial myotomy and de-roofing of the muscle bands on- or off-pump, or as coronary artery bypass grafting of the affected coronary artery beyond the tunnelled segment. Although no mortality was reported with either of these operations, surgical myotomy on deep and extensive myocardial bridges carries the risk of entering the right ventricle, bleeding and aneurysm formation. In addition, in a small percentage of the patients undergoing myotomy, angina recurred. Despite the possibility of competitive flow in the native coronary artery after CABG for myocardial bridging, we did not identify any evidence demonstrating graft occlusion after CABG for myocardial bridging. In conclusion, in extensive and deep myocardial bridgings, CABG may be the treatment of choice that carries low risk, limited complications and excellent symptomatic relief.
- Open Access
- 24 August 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (6) , 1057-1061
Do all patients with prosthetic valve endocarditis need surgery?
A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was ‘do all patients with prosthetic valve endocarditis need surgery?’ Seventeen papers were found using the reported search that represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. These studies compared the outcome and survival between surgically and non-surgically treated patients with prosthetic valve endocarditis. Of these studies, two were prospective observational studies and the rest were retrospective studies. The results of most of these papers were in accordance with the guidelines of the American College of Cardiology and American Heart association. These studies showed that unless a patient is not a surgical candidate, an operation is the treatment of choice in prosthetic valve endocarditis. Surgery should be performed as soon as possible, particularly in haemodynamically unstable patients and those who develop complications such as heart failure, valvular dysfunction, regurgitation/obstruction, dehiscence and annular abscess. In addition to the above indications and cardiac/valvularrelated complications of prosthetic valve endocarditis, infection with Staphylococcus aureus plays an important role in the outcome, and the presence of this micro-organism should be considered an urgent surgical indication in the treatment of prosthetic valve endocarditis. Surgery should be performed before the development of any cerebral or other complications. In contrast, in stable patients with other micro-organisms, particularly those with organisms sensitive to antibiotic treatment who have no structural valvular damage or cardiac complications, surgery can be postponed. The option of surgical intervention can also be revisited if there is a change in response to the treatment. This option is reserved for selected patients only and we conclude that as soon as the diagnosis of prosthetic valve endocarditis is made, cardiac surgeons should be involved.
- 24 August 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (6) , 1057-1061
Open AccessDo all patients with prosthetic valve endocarditis need surgery?
A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was ‘do all patients with prosthetic valve endocarditis need surgery?’ Seventeen papers were found using the reported search that represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. These studies compared the outcome and survival between surgically and non-surgically treated patients with prosthetic valve endocarditis. Of these studies, two were prospective observational studies and the rest were retrospective studies. The results of most of these papers were in accordance with the guidelines of the American College of Cardiology and American Heart association. These studies showed that unless a patient is not a surgical candidate, an operation is the treatment of choice in prosthetic valve endocarditis. Surgery should be performed as soon as possible, particularly in haemodynamically unstable patients and those who develop complications such as heart failure, valvular dysfunction, regurgitation/obstruction, dehiscence and annular abscess. In addition to the above indications and cardiac/valvularrelated complications of prosthetic valve endocarditis, infection with Staphylococcus aureus plays an important role in the outcome, and the presence of this micro-organism should be considered an urgent surgical indication in the treatment of prosthetic valve endocarditis. Surgery should be performed before the development of any cerebral or other complications. In contrast, in stable patients with other micro-organisms, particularly those with organisms sensitive to antibiotic treatment who have no structural valvular damage or cardiac complications, surgery can be postponed. The option of surgical intervention can also be revisited if there is a change in response to the treatment. This option is reserved for selected patients only and we conclude that as soon as the diagnosis of prosthetic valve endocarditis is made, cardiac surgeons should be involved.
- 1 August 2012
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 20 (4) , 392-397
Choice of conduit for coronary artery bypass grafting in poor ventricles
Background: advantages in the use of arterial grafts for coronary artery revascularizations have been reported previously. Objectives: we aimed to compare the outcome and survival rates of different conduits in patients with poor ventricular function (ejection fraction n = 257), (B) total vein grafts (n = 76), and (C) left internal mammary artery and vein grafts (n = 610). Multivariate logistic regression was used to assess the effect of graft type on mortality, while adjusting for patient and disease characteristics. Hospital mortality and 5-year survival rates were compared among the groups. Results: hospital mortality was 8.9% for group A, 11.8% for group B, and 5.7% for group C. Mortality at 5 years was 27.2% for group A, 42.3% for group B, and 28.7% for group C. After risk adjustment, hospital mortality and mid- and long-term mortality showed no significant differences among the groups. Conclusions: patients with poor ventricular function have a high mortality rate in both the short- and long-term with any type of conduit. Mortality rates with total arterial grafts and vein plus arterial grafts were comparable before and after risk adjustment.
- 1 August 2012
- Published by SAGE Publications in Asian Cardiovascular and Thoracic Annals
- Vol. 20 (4) , 392-397
Choice of conduit for coronary artery bypass grafting in poor ventricles
Background: advantages in the use of arterial grafts for coronary artery revascularizations have been reported previously. Objectives: we aimed to compare the outcome and survival rates of different conduits in patients with poor ventricular function (ejection fraction n = 257), (B) total vein grafts (n = 76), and (C) left internal mammary artery and vein grafts (n = 610). Multivariate logistic regression was used to assess the effect of graft type on mortality, while adjusting for patient and disease characteristics. Hospital mortality and 5-year survival rates were compared among the groups. Results: hospital mortality was 8.9% for group A, 11.8% for group B, and 5.7% for group C. Mortality at 5 years was 27.2% for group A, 42.3% for group B, and 28.7% for group C. After risk adjustment, hospital mortality and mid- and long-term mortality showed no significant differences among the groups. Conclusions: patients with poor ventricular function have a high mortality rate in both the short- and long-term with any type of conduit. Mortality rates with total arterial grafts and vein plus arterial grafts were comparable before and after risk adjustment.
- Open Access
- 14 June 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (3) , 494-497
Does surgical debulking for advanced stages of thymoma improve survival?
A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was ‘Does surgical debulking for advanced stages of thymoma improve survival?’ Altogether, only 17 papers were found using the reported search, of which only 10 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated; these studies have mainly reported the survival and recurrence rates after total vs subtotal resection of thymic tumours in patients receiving or not receiving adjuvant chemoradiotherapy. These studies confirmed that complete resection is the best prognostic factor in thymomas. With regard to subtotal tumour resection/debulking, we did not find any randomized controlled trials. The evidence on this topic is scarce and these 10 reported were retrospective reviews of the operative, histology and survival data of patients with thymoma who had subtotal vs partial resection for advanced stages of thymoma. Although debulking surgery for thymoma had positively affected survival, in six studies, the difference failed to reach statistical significance. Three of the studies, on the other hand, showed a higher survival rate in thymomas in which maximum debulking was performed and the treatment was followed by high-dose irradiation. None of these studies showed any benefit in debulking surgery for thymic carcinoma. Besides histology and tumour cell-type, other factors influencing survival included the tumour stage and the presence of symptoms such as myasthenia gravis as a warning sign at an early stage. Current evidence in the literature on the survival after debulking surgery for thymoma is contradictory, and most of the studies do not show any survival benefit after debulking for thymoma. However, debulking surgery minimizes the tumour size and area for irradiation postoperatively, hence it can result in less damage to the adjacent tissue during radiotherapy and may be considered for patients in advanced stages of thymoma in whom extensive radiotherapy will be required. In these cases, however, the risks of surgery followed by radiotherapy or radiotherapy alone should carefully be assessed prior to the initiation of treatment.
- 14 June 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (3) , 494-497
Open AccessDoes surgical debulking for advanced stages of thymoma improve survival?
A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was ‘Does surgical debulking for advanced stages of thymoma improve survival?’ Altogether, only 17 papers were found using the reported search, of which only 10 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated; these studies have mainly reported the survival and recurrence rates after total vs subtotal resection of thymic tumours in patients receiving or not receiving adjuvant chemoradiotherapy. These studies confirmed that complete resection is the best prognostic factor in thymomas. With regard to subtotal tumour resection/debulking, we did not find any randomized controlled trials. The evidence on this topic is scarce and these 10 reported were retrospective reviews of the operative, histology and survival data of patients with thymoma who had subtotal vs partial resection for advanced stages of thymoma. Although debulking surgery for thymoma had positively affected survival, in six studies, the difference failed to reach statistical significance. Three of the studies, on the other hand, showed a higher survival rate in thymomas in which maximum debulking was performed and the treatment was followed by high-dose irradiation. None of these studies showed any benefit in debulking surgery for thymic carcinoma. Besides histology and tumour cell-type, other factors influencing survival included the tumour stage and the presence of symptoms such as myasthenia gravis as a warning sign at an early stage. Current evidence in the literature on the survival after debulking surgery for thymoma is contradictory, and most of the studies do not show any survival benefit after debulking for thymoma. However, debulking surgery minimizes the tumour size and area for irradiation postoperatively, hence it can result in less damage to the adjacent tissue during radiotherapy and may be considered for patients in advanced stages of thymoma in whom extensive radiotherapy will be required. In these cases, however, the risks of surgery followed by radiotherapy or radiotherapy alone should carefully be assessed prior to the initiation of treatment.
- Open Access
- 2 May 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (2) , 273-275
Which stages of thymoma benefit from adjuvant chemotherapy post-thymectomy?
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was ‘Which stages of thymoma benefit from adjuvant chemotherapy post thymectomy?’ Altogether more than 150 papers were found using the reported search, of which only eight represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated; these studies have mainly reported the survival and recurrence rates of post-thymectomy patients who received adjuvant radiotherapy or chemoradiotherapy, and adjuvant radiotherapy alone was only used in a small group of patients in these studies. We did not find any randomized controlled trials comparing adjuvant chemotherapy with chemo/radiotherapy and, due to a very small incidence of this tumour, it is unlikely to see any trials in future. Studies were mainly retrospective or institutional reports and showed that, despite the high sensitivity of this tumour to chemotherapy agents and the use of chemotherapy as one of the main treatment modalities in the advanced stages of thymoma, current data are not supporting postoperative chemotherapy as a sole adjuvant treatment in advanced stages of thymoma. We conclude that, in patients with thymoma, surgical resection with or without radiation therapy is the gold standard treatment for early-stage disease (I and II). Adjuvant radiotherapy/chemoradiotherapy should be considered for Masaoka stage III (A and B) or above, and it is also advised to add adjuvant therapy for all patients with cortical fenestration, even in stages I and II. But there is no evidence that chemotherapy alone improves the survival in patients with completely resected stage III and IV thymomas and thymic carcinoma. In patients with extra-radiation field disease, however, the use of chemotherapy can potentially improve survival but no follow-up data on this group of patients are available.
- 2 May 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (2) , 273-275
Open AccessWhich stages of thymoma benefit from adjuvant chemotherapy post-thymectomy?
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was ‘Which stages of thymoma benefit from adjuvant chemotherapy post thymectomy?’ Altogether more than 150 papers were found using the reported search, of which only eight represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated; these studies have mainly reported the survival and recurrence rates of post-thymectomy patients who received adjuvant radiotherapy or chemoradiotherapy, and adjuvant radiotherapy alone was only used in a small group of patients in these studies. We did not find any randomized controlled trials comparing adjuvant chemotherapy with chemo/radiotherapy and, due to a very small incidence of this tumour, it is unlikely to see any trials in future. Studies were mainly retrospective or institutional reports and showed that, despite the high sensitivity of this tumour to chemotherapy agents and the use of chemotherapy as one of the main treatment modalities in the advanced stages of thymoma, current data are not supporting postoperative chemotherapy as a sole adjuvant treatment in advanced stages of thymoma. We conclude that, in patients with thymoma, surgical resection with or without radiation therapy is the gold standard treatment for early-stage disease (I and II). Adjuvant radiotherapy/chemoradiotherapy should be considered for Masaoka stage III (A and B) or above, and it is also advised to add adjuvant therapy for all patients with cortical fenestration, even in stages I and II. But there is no evidence that chemotherapy alone improves the survival in patients with completely resected stage III and IV thymomas and thymic carcinoma. In patients with extra-radiation field disease, however, the use of chemotherapy can potentially improve survival but no follow-up data on this group of patients are available.
- Open Access
- 19 April 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42 (4) , 653-658
A propensity-matched comparison of survival after lung resection in patients with a high versus low body mass index
An inverse relationship between body mass index (BMI) and the risk of lung cancer has been reported in several studies. In this study, we aimed to assess whether BMI can affect survival after lung resection for cancer. We reviewed patient data for a 10-year period; 337 patients with BMI ≥30 who underwent lung resection for non-small cell lung cancer were identified. This group of patients was matched at a ratio of 1:1 to a group with BMI P = 0.02). This difference remained significant after adjusting for all the characteristics, suggesting a significantly higher survival rate in the group with BMI ≥30 (P = 0.04). Unlike in breast cancer, a high BMI in lung cancer patients after resection has protective effects. This may be due to the better nutritional status of the patient, a less aggressive cancer type that has not resulted in weight loss at the time of presentation or it may be due to certain hormones released from the adipose tissue. BMI can be a predictor of outcome after lung resection in cancer patients.
- 19 April 2012
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 42 (4) , 653-658
Open AccessA propensity-matched comparison of survival after lung resection in patients with a high versus low body mass index
An inverse relationship between body mass index (BMI) and the risk of lung cancer has been reported in several studies. In this study, we aimed to assess whether BMI can affect survival after lung resection for cancer. We reviewed patient data for a 10-year period; 337 patients with BMI ≥30 who underwent lung resection for non-small cell lung cancer were identified. This group of patients was matched at a ratio of 1:1 to a group with BMI P = 0.02). This difference remained significant after adjusting for all the characteristics, suggesting a significantly higher survival rate in the group with BMI ≥30 (P = 0.04). Unlike in breast cancer, a high BMI in lung cancer patients after resection has protective effects. This may be due to the better nutritional status of the patient, a less aggressive cancer type that has not resulted in weight loss at the time of presentation or it may be due to certain hormones released from the adipose tissue. BMI can be a predictor of outcome after lung resection in cancer patients.
- Open Access
- 21 December 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (4) , 806-811
Does the outcome improve after radiofrequency ablation for atrial fibrillation in patients undergoing cardiac surgery? A propensity-matched comparison
Preoperative atrial fibrillation (AF) significantly reduces the survival rate post cardiac surgery. It has been shown that patients in persistent or paroxysmal AF have higher mid- and long-term mortality post cardiac surgery compared with those in sinus rhythm. In this study we aimed to assess whether radiofrequency (RF) ablation during cardiac surgery in these patients improves the survival. For a period of 5 years (2005–10), we studied all the patients who underwent ablation for AF during cardiac surgery for persistent/paroxysmal AF in our institution. We used RF ablation on 113 patients who had AF for P value = 0.038). Despite, the similar postoperative outcome with or without ablation in persistent/paroxysmal AF, 5-year survival was found to be significantly higher with the ablation during cardiac surgery. This improvement can be due to the fall in the incidence of cerebro-vascular events or bleeding with AF or warfarin. Ablation during cardiac surgery is a simple and quick procedure and should be considered if indicated.
- 21 December 2011
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 41 (4) , 806-811
Open AccessDoes the outcome improve after radiofrequency ablation for atrial fibrillation in patients undergoing cardiac surgery? A propensity-matched comparison
Preoperative atrial fibrillation (AF) significantly reduces the survival rate post cardiac surgery. It has been shown that patients in persistent or paroxysmal AF have higher mid- and long-term mortality post cardiac surgery compared with those in sinus rhythm. In this study we aimed to assess whether radiofrequency (RF) ablation during cardiac surgery in these patients improves the survival. For a period of 5 years (2005–10), we studied all the patients who underwent ablation for AF during cardiac surgery for persistent/paroxysmal AF in our institution. We used RF ablation on 113 patients who had AF for P value = 0.038). Despite, the similar postoperative outcome with or without ablation in persistent/paroxysmal AF, 5-year survival was found to be significantly higher with the ablation during cardiac surgery. This improvement can be due to the fall in the incidence of cerebro-vascular events or bleeding with AF or warfarin. Ablation during cardiac surgery is a simple and quick procedure and should be considered if indicated.
- 1 October 2011
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 92 (4) , 1391-1395
A Comparison of Outcome in Patients With Preoperative Atrial Fibrillation and Patients in Sinus Rhythm
- 1 October 2011
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 92 (4) , 1391-1395
A Comparison of Outcome in Patients With Preoperative Atrial Fibrillation and Patients in Sinus Rhythm
- Open Access
- 10 August 2011
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 13 (5) , 523-525
Management of a chronic Stanford type B dissection in a patient with a right-sided aortic arch
We report the case of a 44-year-old male with a right-sided aortic arch who presented with dissection extending from his distal arch to his left comm
- 10 August 2011
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 13 (5) , 523-525
Open AccessManagement of a chronic Stanford type B dissection in a patient with a right-sided aortic arch
We report the case of a 44-year-old male with a right-sided aortic arch who presented with dissection extending from his distal arch to his left comm
- 1 July 2011
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 92 (1) , 338-339
Polypoid Pseudomyxoma of Ascending Aorta After Replacement With a Dacron Graft
- 1 July 2011
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 92 (1) , 338-339
Polypoid Pseudomyxoma of Ascending Aorta After Replacement With a Dacron Graft